The Hypothesis

I suspect that age-related stiffening of the extracellular matrix (ECM)—driven specifically by advanced glycation end-product (AGE) crosslinking—acts as a chronic biophysical agonist that pulls down the activation threshold for the MRGPRX2 receptor (Mrgprb2 in rodents). This essentially represents a "low-pass filter" failure in aging connective tissue. While young mast cells (MCs) require high-intensity mechanical stimuli to trigger Substance P (SP) release and degranulation, aged MCs likely exist in a state of chronic, low-grade degranulation. It is a fundamental shift in the mechanical-to-chemical signaling gateway.

Mechanistic Reasoning

Current models show that mechanical stress on tenocytes releases SP, which then activates MRGPRX2 on mast cells to drive calcium mobilization and ECM degradation [https://pmc.ncbi.nlm.nih.gov/articles/PMC11169467/]. However, I don't think the aging process is just a matter of higher SP volume. We are likely looking at a change in receptor sensitivity dynamics.

1. Stiffness-Gated Sensitization: In aged tissues, the increased elastic modulus of the ECM provides constant mechanical feedback to residing tenocytes. This likely results in a constitutive, sub-clinical leakage of SP.
2. GPCR Signal Drift: Chronic exposure to this background SP, paired with age-related changes in membrane fluidity, likely impairs GRK-mediated desensitization of MRGPRX2. This leads to "Signal Drift," where the receptor fails to internalize or reset. This effectively turns a phasic response into a chronic inflammatory leak.
3. The Proteolytic Feedback Loop: This sustained MRGPRX2 activation upregulates MMPs and NGF [https://pmc.ncbi.nlm.nih.gov/articles/PMC11169467/], further degrading functional collagen while increasing fibronectin affinity. It creates a pathological loop: the more the ECM is disorganized, the more mechanical instability is introduced, which only drives further SP release.

Integrating the Bayesian Analytical Gap

Traditional frequentist approaches (p < 0.05) often fail to capture the "leakage" inherent in aging systems, usually dismissing low-level degranulation as background noise. I'd argue that applying Bayesian hierarchical modeling—similar to the frameworks used in complex oncology trials [https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1548997/full]—to MRGPRX2 signaling will show that the posterior probability of degranulation in aged tissue is significantly higher at lower ligand concentrations than in young tissue.

We have to move away from treating mast cell activation as a binary "on/off" status. In the context of aging, the "noise" is the pathology. If we model MRGPRX2 activation as a probability distribution influenced by ECM stiffness, we'll likely find that the "set point" for inflammaging is mechanically determined.

Testability and Falsification

We can test this through several avenues:

• AFM-Coupled Degranulation Assays: We can use Atomic Force Microscopy to simulate age-matched ECM stiffness on hydrogels and measure MRGPRX2-dependent Ca2+ influx in MCs.
• Pharmacological Reversal: By using AGE-breakers like Alagebrium in aged mice to restore ECM elasticity, we can see if the hypothesis holds. Restoring physical elasticity should significantly reduce spontaneous MRGPRX2-mediated degranulation and the secretion of pro-inflammatory cytokines like IL-1β and NGF [https://pmc.ncbi.nlm.nih.gov/articles/PMC11169467/], even without adding exogenous SP.
• Falsification: This hypothesis is proven wrong if MRGPRX2 knockout aged mice still show identical connective tissue degradation, or if restoring ECM elasticity has no measurable effect on the basal degranulation rate of resident mast cells.